Drug Profile
Research programme: metabolic disorders therapy - Inozyme Pharma
Alternative Names: ENPP-1; Genn Biologics; SBC-104; SBC-106; SBC-342Latest Information Update: 21 Jul 2020
Price :
$50
*
At a glance
- Originator Synageva BioPharma
- Developer Alexion Pharmaceuticals
- Class Enzymes; Recombinant proteins
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Calcinosis; Metabolic disorders
Most Recent Events
- 17 Jul 2020 Inozyme Pharma acquires intellectual property and assets focusing on ENPP1 gene deficiencies from Alexion Pharmaceuticals
- 27 Jul 2017 Discontinued - Preclinical for Calcinosis in USA (Parenteral) as a result of Alexion's redefined R&D strategy
- 27 Jul 2017 Discontinued - Preclinical for Metabolic disorders in USA as a result of Alexion's redefined R&D strategy